article22 December 2021 | By Prof Axel Glasmacher (University of Bonn), Prof Jaap Verweij MD PhD (Erasmus University Medical Centre), Prof John Smyth (University of Edinburgh)
From the Cancer Drug Development Forum (CDDF), John Smyth (Chairman), Axel Glasmacher (Treasurer) and Jaap Verweij (Managing Director) clarify the importance of a collaborative industry approach to cancer therapy development and highlight the most pressing challenges for discussion in their meetings and workshops.